Clinical trials: Pregnancy Outcome
Infertility, Aneuploidy
Single Embryo TrAnsfeR of Euploid Embryo
The purpose of the current study is to evaluate the effect of preimplantation genetic screening (PGS) by next generation sequencing (NGS) compared to standard morphological assessment of embryos on pregnancy rates through a…
- Trial name
- STAR (NCT02268786)
- Testing
- Preimplantation Genetic Screening by NGS
- Where
- 38 sites in United States, Australia and 2 more
- Volunteers
- 661 people
- Sponsor
- Illumina, Inc.
Ovarian Cancer
Non-interventional Study to Collect Real-world Clinical and Patient-reported Outcomes in Ovarian Cancer
This prospective non-interventional study is intended to generate new data and insights into first-line (1L) treatment of newly diagnosed advanced high-grade epithelial Ovarian cancer (OC) in Germany relevant for patients…
- Trial name
- SCOUT-1 (NCT04830709)
- Where
- 89 sites in Germany
- Volunteers
- 752 people
- Sponsor
- AstraZeneca
Pregnancy Related
Safety Study for Prospective Assessment of Pregnancy Outcomes in Patients Treated With Tildrakizumab
This study will utilize a prospective, observational, exposure cohort design to examine pregnancy and infant outcomes in women and infants who are exposed to tildrakizumab during pregnancy to treat an approved indication.
- Trial name
- NCT03992729
- Testing
- Pregnant women exposed to tildrakizumab, Pregnant women not exposed to tildrakizumab
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Pregnancy, Neonates
Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05787 (P05712)
The objective of this trial was to evaluate whether Corifollitropin Alfa treatment for the induction of multifollicular growth in women undergoing controlled ovarian stimulation (COS) prior to in vitro fertilization (IVF) or…
- Trial name
- NCT00703014
- Testing
- Corifollitropin Alfa 150 μg, 200 IU RecFSH/Follitropin beta (Days 1 to 7), 200 IU RecFSH/Follitropin beta (Days 8 to hCG)
- Volunteers
- 541 people
- Sponsor
- Organon and Co
Sickle Cell Disease
Crizanlizumab Pregnancy Outcomes Intensive Monitoring
This was a non-interventional study to evaluate pre-specified pregnancy and infant outcomes in women treated with crizanlizumab during pregnancy or within 105 days before the last menstrual period (LMP).
- Trial name
- PRIM (NCT07554547)
- Where
- Switzerland
- Volunteers
- 13 people
- Sponsor
- Novartis Pharmaceuticals